1H NMR spectroscopy studies of Huntington's disease. Correlations with CAG repeat numbers

Neurology

Volumn 50, Issue 5, 1998, Pages 1357-1365

  Jenkins, B G ^a   Rosas, H D ^a   Chen, Y C I ^a   Makabe, T ^a   Myers, R ^b   MacDonald, M ^a   Rosen, B R ^a   Beal, M Flint ^a   Koroshetz, W J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; LACTIC ACID; PROTON;

ADULT; ARTICLE; CELL LOSS; CHROMOSOME 4; CLINICAL ARTICLE; ENERGY METABOLISM; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TANDEM REPEAT; TASK PERFORMANCE; BRAIN; CASE CONTROL STUDY; COMPARATIVE STUDY; CORPUS STRIATUM; GENETICS; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; STATISTICAL MODEL; TRINUCLEOTIDE REPEAT;

ADULT; BRAIN; CASE-CONTROL STUDIES; CORPUS STRIATUM; ENERGY METABOLISM; FEMALE; HUMANS; HUNTINGTON DISEASE; LACTIC ACID; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; TRINUCLEOTIDE REPEATS;

EID: 0031596998     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1357     Document Type: Article

References (44)

1. The Huntington's Disease Collaborative Research Group. The novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992;42:733.
3. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
4. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-700.
5. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative diseases. Trends Physiol Sci 1990; 11:379-387.
6. Olanow CW. A radical hypothesis for neuronal degeneration. Trends Neurosci 1993;16:439-443.
7. Schulz JB, Beal MF. Mitochondrial dysfunction in movement disorders. Curr Opin Neurol 1994;7:333-339.
8. Wallace DW. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 1992;256:628-632.
9. Ludolph A, Seelig M, Ludolph A, et al. 3-Nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1992;18:492-498.
10. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-7109.
11. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993;13:4181-4191.
12. Brouillet E, Jenkins BG, Hyman BT, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 1993;60:356-359.
13. 18FDG and computed tomographic scan. Ann Neurol 1982;12:425-434.
14. Kuwert T, Lange HW, Langen K-J, Herzog H, Aulich A, Feinendegen LE. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease Brain 1990;113:1405-1423.
15. Leenders KL, Fracowiak RSJ, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured using positron emission tomography Mov Disord 1986;1:69-77.
16. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtybel W, Hayden MR. Cortical glucose metabolism in Huntington's disease. Neurology 1992;42:223-229.
17. Young AB, Penney JB, Starosta-Rubenstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurologic features and functional decline Ann Neurol 1986;20:296-303.
18. Jenkins B, Koroshetz W, Beal MF, Rosen B. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology 1993;43:2689-2695.
19. Strong TV, Tagle DA, Valdes JM, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissue. Nature Genet 1993;5:259-265.
20. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991;48:800-804.
21. O'Brien CF, Miller C, Goldblatt D, et al. Extraneural metabolism in early Huntington's disease. Ann Neurol 1990;28:300-301.
22. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87:493-506.
23. 10. Ann Neurol 1997;41:160-165.
24. Martin WRW, Hanstock C, Hodder J, Allen PS. Brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy. Ann Neurol 1996;40: 538. Abstract.
25. Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 1997;62:27-30.
26. Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992;31: 69-75.
27. Furtado S, Suchowersky O, Reweasle NB, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol 1996;39:132-136.
28. Penney JB Jr, Vonsattel J-P, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41: 689-692.
29. Snell RG, MacMillan JC, Cheadle JP, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nature Genet 1993;4:393-397.
30. Illarioshkin SN, Igarashi S, Onodera O, et al. Trinucleotide repeat length and rate of progression of Huntington's disease. Ann Neurol 1994;36:630-635.
31. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology 1996;46:527-531.
32. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genet 1993;4:398-403.
33. Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nature Genet 1993;4:387-392.
34. Grafton ST, Mazziotta JC, Pahl JJ, et al. A comparison of neurological, metabolic, structural and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 1990;28: 614-621.
35. Mazziotta JC, Phelps ME, Pahl JI, et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 1987;316:356-367.
36. Urejnak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance unambiguously identifies neural cell types. J Neurosci 1993;13:981-989.
37. Chang L, Ernst T, Tomatore C, et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997;48:836-845.
38. Chen YI, Galpern W, Brownell A-L, et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis and behavioral data. Magn Reson Med 1997;38:389-398.
39. Sappey-Marinier D, Calabrese G, Fein G, Hugg JW, Biggins C, Weiner MW. Effect of photic stimulation on human visual cortex lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J Cerebr Blood Flow Metab 1992;12: 584-592.
40. 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA 1991;88:5829-5831.
41. 1H-MRS study. Brain Res 1995;670:326-328.
42. Detre JA, Williams DS, Koretsky AP. Nuclear magnetic resonance determination of flow, lactate, and phosphate metabolites during amphetamine stimulation of the rat brain. NMR Biomed 1990;3:272-278.
43. Jenkins BG, Burns L, Pakzaban P, et al. Spectroscopic studies of neurochemical changes in a primate model of neurodegeneration and neurotransplantation. Proc Soc Magn Reson 1994: 1423. Abstract.
44. Dunlop DS, McHale DM, Lajtha A. Decreased brain N-acetylaspartate in Huntington's disease. Brain Res 1992; 580:44-48.